NasdaqGM:APGEBiotechs
Why Apogee Therapeutics (APGE) Is Up 8.0% After Phase 2 Win And $1.3 Billion Blackstone Deal
Apogee Therapeutics recently reported positive 16-week Phase 2 APEX data for its anti-IL-13 antibody zumilokibart in moderate-to-severe atopic dermatitis and entered a financing collaboration with Blackstone Life Sciences for up to US$1.30 billion in flexible, non-dilutive capital tied to future royalty payments.
The combination of clinically meaningful efficacy, an extended dosing profile and a large, royalty-based funding package positions zumilokibart as a potential cornerstone asset in...